Introduction
Borderline personality disorder (BPD) is characterized by symptoms (e.g. impulsivity) that are difficult to treat (Soloff and Fabio, 2008) . Research is needed to better understand both the underlying neural mechanisms of BPD and the mechanisms of existing treatments. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) studies have identified hypometabolism in frontally mediated networks associated with impaired emotion processing and impulsivity in BPD (Mauchnik and Schmahl, 2010; Schulze et al., 2016; Soloff et al., 2000) . Our FDG-PET cross-sectional data reported an association between frontal hypometabolism with hostility in BPD (Schulz et al., 2013) .
Olanzapine reduces BPD symptoms (Schulz et al., 2008) and has induced metabolism changes in other psychiatric disorders (Guo et al., 2017) . It is crucial to understand how olanzapine impacts identified frontal hypometabolism in BPD to better inform treatment development.
The current study used FDG-PET to measure brain changes associated with response to an eight-week olanzapine intervention. Because FDG-PET depicts glutamatergic synaptic activity coupled with glucose consumption, it allowed us to examine correlations between symptomatology change and (i) brain metabolism change and (ii) baseline metabolism.
The identification of neural changes underlying successful olanzapine treatment can inform future treatment strategies to better target these brain changes and optimize treatment outcomes in BPD.
Methods

Participants
We recruited 17 BPD female subjects aged 18-45 years old with a BPD diagnosis (DSM-IV).
(Inclusion/exclusion criteria in Supplementary Material).
Clinical assessments
Patients underwent a diagnostic assessment (Structured Clinical
Interview, DSM-IV-TR), Structured Interview for DSM-IV Personality, a physical exam, blood tests and urinalysis. The Brief Psychiatric Rating Scale (BPRS), Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), Barratt Impulsivity Scale (BIS), the Hamilton Depression Scale (HAM-D), and Buss-Durkee Hostility Index (BDHI), and Symptom Checklist 90 (SCL-90) were administered at baseline and every week during the eight-week administration of olanzapine.
Imaging procedures
Pre-and post-treatment FDG-PET scans were collected with a Siemens Biograph 16 (details in Supplementary Material).
Medication treatment procedures
After baseline FDG-PET scan, subjects were given olanzapine 2.5 mg daily. Dose was titrated up to 7.5 mg daily by week-4 and then held constant until the end of week-eight. Patients underwent a second FDG-PET scan after completing 8-weeks of olanzapine treatment.
Imaging analysis
Preprocessing for pre-and post-treatment FDG-PET data was conducted using FSL. The first emission scan was affine registered to standard space (Montreal Neurological Institute). The second emission scan was affine registered to the registered first emission scan and filtered (full width half maximum: 12 mm). After non-brain masking, each volume was scaled (M = 1000) and z-transformed. For analysis of metabolism change, the z-transformed first emission scan was subtracted from the z-transformed second emission scan.
Statistical analyses
To identify regions with significant pre-post treatment change, voxel-wise within-group paired t-tests were conducted (AFNI-3dttest). 
